Crystal Structure of the Pyrazinamidase of Mycobacterium tuberculosis: Insights into Natural and Acquired Resistance to Pyrazinamide

Pyrazinamidase (PncA) activates the first-line antituberculous drug pyrazinamide into pyrazinoic acid. The crystal structure of the Mycobacterium tuberculosis PncA protein has been determined, showing significant differences in the substrate binding cavity when compared to the pyrazinamidases from Pyrococcus horikoshii and Acinetobacter baumanii. In M. tuberculosis, this region was found to hold a Fe2+ ion coordinated by one aspartate and three histidines, one of them corresponding to His57 which is replaced by Asp in Mycobacterium bovis, a species naturally resistant to pyrazinamide. The binding cavity also contains a Cys138-Asp8-Lys96 motif evocating a cysteine-based catalytic mechanism. Mutants have been constructed and investigated by kinetic and thermal shift assays, highlighting the importance of protein folding and thermal stability in the pyrazinamidase activity.

[1]  Joseph D. Kwasnoski,et al.  High-density miniaturized thermal shift assays as a general strategy for drug discovery. , 2001, Journal of biomolecular screening.

[2]  R. Gilman,et al.  Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. , 2009, Tuberculosis.

[3]  W. Mcdermott,et al.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli. , 1967, The American review of respiratory disease.

[4]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[5]  Wolfgang Kabsch,et al.  Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants , 1993 .

[6]  M. Doyle,et al.  Assessing compound binding to the Eg5 motor domain using a thermal shift assay. , 2009, Analytical biochemistry.

[7]  T. Kirikae,et al.  Development and Evaluation of a Line Probe Assay for Rapid Identification of pncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis Strains , 2007, Journal of Clinical Microbiology.

[8]  J. Blanchard,et al.  Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis. , 2010, Biochemistry.

[9]  D. Mitchison,et al.  The curious characteristics of pyrazinamide: a review. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  F. Doustdar,et al.  Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. , 2009, Microbial drug resistance.

[11]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[12]  V. Jarlier,et al.  Characterization of New Mutations in Pyrazinamide-Resistant Strains of Mycobacterium tuberculosisand Identification of Conserved Regions Important for the Catalytic Activity of the Pyrazinamidase PncA , 1999, Antimicrobial Agents and Chemotherapy.

[13]  J. Bates,et al.  Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene , 1997, Journal of clinical microbiology.

[14]  P. Juréen,et al.  Pyrazinamide Resistance and pncA Gene Mutations in Mycobacterium tuberculosis , 2008, Antimicrobial Agents and Chemotherapy.

[15]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[16]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[17]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[18]  S H Kim,et al.  Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. , 2001, Biochemistry.

[19]  Ying Zhang,et al.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.

[20]  L. Bi,et al.  Mutations Found in the pncA Gene of Mycobacterium tuberculosis in Clinical Pyrazinamide-resistant Isolates from a Local Region of China , 2009, The Journal of international medical research.

[21]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[22]  Insight to pyrazinamide resistance inMycobacterium tuberculosisby molecular docking , 2009, Bioinformation.

[23]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[24]  R. Gilman,et al.  Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance. , 2010, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[25]  S. Cameron,et al.  Specificity and mechanism of Acinetobacter baumanii nicotinamidase: implications for activation of the front-line tuberculosis drug pyrazinamide. , 2009, Angewandte Chemie.

[26]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[27]  A. Upton,et al.  Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand , 2009, Pathology.

[28]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[29]  I. Callebaut,et al.  Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. , 2001, The Biochemical journal.

[30]  K Henrick,et al.  Electronic Reprint Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions , 2022 .

[31]  Fei Long,et al.  REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. , 2004, Acta crystallographica. Section D, Biological crystallography.

[32]  Li-Jun Bi,et al.  Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase , 2008, The FEBS journal.